Topic:

November 2023

Lupus Canada Recipient of Community Services Recovery Fund

blog image

November 1, 2023 – We are pleased to announce that Lupus Canada has been selected as a funding recipient of the Government of Canada’s Community Services Recovery Fund which supports Community Service Organizations as they adapt for the long-term impacts of the COVID-19 pandemic. The Community Services Recovery Fund is a one-time $400 million investment from the Government of Canada to support community service organizations, including charities, non-profits and Indigenous governing bodies, as they adapt and modernize their organizations so they can continue serving their communities.

Lupus Canada’s awarded funding will directly support the “Transition to Remote Operations – A Recovery, Efficiency and Modernization Plan”. This funding is a game-changer and will enable Lupus Canada to make significant strides in our mission to improve the lives of those impacted by lupus.

As a direct result of this funding, Lupus Canada will update technological supports, streamline and optimize remote operations, as well as spearhead innovative solutions to enhance our services and outreach. Ultimately, this means we will be able to connect with our lupus community more efficiently and effectively with improved systems in place.

Nearly 5,500 Community Service Organizations from coast to coast have received funding to build their organizational capacity and adapt for the COVID-19 pandemic recovery. The Community Services Recovery Fund is being delivered through three National Funders – Canadian Red Cross, Community Foundations of Canada, and United Way Centraide Canada.

Lupus Canada would like to thank the Government of Canada, as well as the Canadian Red Cross, for their support as well as the community that continues to support our mission. It wouldn’t be possible without you and your unwavering commitment has made this possible. Thank you.

@redcrosscanada

Lupus Blog Articles: Lupus lorem ipsum dolor sit amet est requiem deste natur.

Anifrolumab (Saphnelo) listed in SK

Read

Belimumab (Benlysta) listed in AB, NL & NIHB

Read

Belimumab (Benlysta) listed in ON

Read